Revenue segments as reported by the company.

Premiums

Product revenue

Administrative fees and other revenue

Net investment income

Net gains on financial instruments

Gain on sale of business

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit expense

Selling, general and administrative

Interest expense

Amortization of other intangible assets

Loss on extinguishment of debt

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Elevance Health Inc

Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. The firm supports consumers, families, and communities across the entire care journey, connecting them to the care, support, and resources they need to lead healthier lives. It offers health plans and clinical, behavioral, pharmacy, and complex-care solutions which promote whole health. The company was founded in 1944 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Elevance Health reports robust Q4 earnings, eyes margin optimization

Elevance Health's strong Q4 2022 performance, strategic acquisitions, and focus on margin optimization position the company for continued growth. With a clear outlook for 2023, emphasizing membership expansion and margin recovery, the company is poised for success. Challenges in optimizing margins and managing cost structures are balanced by growth opportunities and strategic initiatives.

Elevance Health reports robust Q1 growth and innovation in healthcare

Elevance Health Inc demonstrated strong financial performance and growth in Q1 2023, driven by increased membership and solid operating results.
The company's focus on advocacy, innovation, and sustainability, along with strategic investments in healthcare capabilities, positions it for continued success.
While facing challenges in cost management and strategic partnerships, Elevance Health is well-positioned to capitalize on opportunities in specialty care and value-based models.
Overall, Elevance Health's commitment to whole health, innovation, and value-based care sets a positive trajectory for future growth and industry leadership.

Elevance Health Inc posts robust Q2 earnings, eyes value-based care

Elevance Health Inc reported strong Q2 earnings, raised adjusted EPS outlook to over $32.85 for the year, and emphasized a focus on value-based care and digital solutions. While facing margin pressure in Carelon, the company remains confident in its strategy execution and performance for 2023 and beyond.

Elevance Health excels in Q3, eyes growth through strategic actions

Elevance Health's Q3 performance was strong, with a focus on operational efficiency and strategic investments. Challenges in Medicare ratings were addressed through proactive measures, while opportunities lie in growth acceleration and strategic partnerships. The company remains on track to achieve its long-term growth targets.

Elevance Health Inc surpasses earnings expectations, eyes growth opportunities

Elevance Health Inc's strong financial performance in Q4 2023 and full-year results, coupled with strategic initiatives in expanding capabilities and enhancing operational efficiency, position the company for continued success. Challenges in commercial repricing and Medicaid dynamics are being addressed, while opportunities in Medicare Advantage and strategic investments offer avenues for growth.

Elevance Health posts robust Q1 earnings, eyes strategic growth

Elevance Health demonstrated strong financial performance in Q1, with revenue growth and margin expansion in key segments.
While facing challenges like potential Medicare rate cuts, the company is leveraging partnerships and acquisitions for growth.
Opportunities lie in expanding service offerings, geographic footprint, and optimizing Medicaid margins for long-term sustainability.

Elevance Health Inc reports robust earnings growth and strategic wins

Elevance Health's Q2 performance reflects strong earnings growth and reaffirmed guidance, driven by solid segment performance and new business wins.
The company's strengths lie in its high Medicare rating, robust revenue growth in services, and strategic focus on value creation.
Challenges include sustaining growth momentum, managing funding cuts, and effectively integrating recent acquisitions for long-term success.
Opportunities exist in accelerating capabilities, expanding market share, optimizing operations, and leveraging workplace recognition for talent attraction and innovation.

Elevance Health faces Medicaid challenges, sees growth in AI investments

Elevance Health's Q3 earnings were impacted by elevated medical costs in Medicaid, leading to a reduction in full-year outlook. Despite challenges in the Medicaid business, the company's Medicare Advantage and Commercial businesses are performing well. Investments in AI and expansion of Carelon Services present growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Commercial and Specialty Business, Government Business, CarelonRx, and Other. The Commercial and Specialty Business segment provides insurance products and services such as stop loss, dental, vision, life, disability and supplemental health insurance. The Government Business segment includes medicare and medicaid businesses, national government services, and services provided to the federal government. The CerelonRx segment offers formulary management, pharmacy networks, prescription drug database, member services, and mail order capabilities. The Other segment is involved in health services business focused on quality of healthcare by enabling and creating new care delivery and payment models. The company was founded in 1944 and is headquartered in Indianapolis, IN.

Elevance Health, Inc. (NYSE:ELV ) Q2 2023 Earnings Conference Call July 19, 2023 8:30 AM ET Company Participants Steve Tanal - VP of IR Gail Boudreaux - President and CEO John Gallina - CFO Peter Haytaian - President of Carelon Morgan Kendrick - President of Commercial and Specialty Health Benefits Division Felicia Norwood - President of Government Health Benefits Division Conference Call Participants A.J. Rice - Credit Suisse Lance Wilkes - Bernstein Justin Lake - Wolfe Research Michael Ha - Morgan Stanley Josh Raskin - Nephron Research George Hill - Deutsche Bank Lisa Gill - JPMorgan Kevin Fischbeck - Bank of America Scott Fidel - Stephens Steven Valiquette - Barclays Nathan Rich - Goldman Sachs Operator Ladies and gentlemen, thank you for standing by, and welcome to the Elevance Health Second Quarter Earnings Conference Call.

Elevance Health, Inc. (ELV) Q2 2023 Earnings Call Transcript

Elevance Health's (ELV) Q2 results benefit from an expanding customer base and solid pharmacy product revenues. Adjusted net income is expected to be more than $32.85 per share for 2023.

Elevance Health (ELV) Beats on Q2 Earnings, Ups '23 Profit View

Elevance Health has delivered second-quarter earnings and full-year profit guidance that beat expectations, sending its shares more than 6% higher in early Wednesday morning trade.  The health insurance provider reported a 13% rise in operating revenue to $43.4 billion for the quarter ended June 30, 2023, as it raised premiums in its Health Benefits business and due to membership growth in Medicaid and Medicare.

Elevance Health rises on 2Q earnings beat, revised 2023 guidance

Carvana

Stock markets kept gaining ground early Wednesday. Carvana announced a debt restructuring deal that will buy it time before having to repay obligations.

These 2 Stocks Are Soaring Wednesday Morning

The headline numbers for Elevance Health (ELV) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Elevance Health (ELV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Elevance Health Inc.'s stock ELV, +1.49% rose 5% in premarket trade Wednesday, after the health insurer's second-quarter earnings handily beat estimates. The company posted net income of $1.853 billion, or $7.79 a share, for the quarter, up from $1.637 billion, or $6.73 a share, in the year-earlier period.

Elevance Health's stock up 5% after earnings beat estimates

Elevance Health Inc raised its full-year profit forecast on Wednesday, banking on strength in its government-backed health insurance business as well as a boost in its commercial unit that sells plans to employer groups and individuals.

Elevance Health raises 2023 profit forecast

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health, Inc. (NYSE: ELV) reported second quarter 2023 results reflecting strong financial performance, including double-digit growth in revenue, operating earnings, and adjusted earnings per share. “Our solid execution and continued progress of our strategy to become a lifetime trusted health partner resulted in strong second quarter and first half results,” said Gail K. Boudreaux, President and CEO. “Our focused efforts to optimize our mature businesses,.

Elevance Health Reports Second Quarter 2023 Results

Abbott Labs

Home Depot

Intercontinental Exchange

Thermo Fisher Scientific

Tractor Supply

Toro

UnitedHealth Group

Visa

The article presents a monthly series of 10 top-ranked dividend growth stocks for further research and potential investment. The stocks are ranked based on quality scores, with tie-breaking metrics including dividend safety scores, credit ratings, and forward dividend yield. The top three stocks for this month are Visa, UnitedHealth, and Intercontinental Exchange. The article also provides key metrics and fair value estimates for each stock, and suggests that Tractor Supply Company passes all selection criteria for adding new positions to the author's DivGro portfolio.

10 Dividend Growth Stocks For July 2023

As of July 14, 2023, Elevance Health Inc ( ELV , Financial) has seen a price change of 5.06%, reaching $438.75 per share. With a market capitalization of $104 billion, Elevance Health's financial metrics reveal an interesting picture.

Elevance Health (ELV): A Modestly Undervalued Stock with Strong Growth Prospects

Elevance Health's (ELV) second-quarter results are likely to reflect rising memberships in Medicare Advantage, Medicaid, Vision and Dental Administration businesses.

Will Carelon Growth Aid Elevance Health's (ELV) Q2 Earnings?

Elevance Health Inc ( ELV , Financial) is a leading health insurer in the U.S., catering to approximately 48 million medical members as of December 2022. The company provides employer, individual, and government-sponsored coverage plans.

Unveiling the Modest Undervaluation of Elevance Health Inc (ELV)

Elevance Health (ELV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Elevance Health (ELV) Earnings Expected to Grow: Should You Buy?

Elevance Health's stock price has suffered due to uncertainties in the health industry and bond market, but the current price offers strong growth potential. The company's Carelon segment saw a 17.7% YoY increase in operating revenue, and its recent acquisition of Louisiana Health Service & Indemnity Company offers regional opportunities. Despite a drop in share price, ELV is considered a solid investment due to its dividend and cash flows, with the potential for a valuation of $552 per share in 2023, a 23% increase from the current price.

Elevance Health: Beaten Down Share Price Offers Solid Potential

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) will release second quarter 2023 financial results on July 19, 2023, at 6:00 a.m. Eastern Daylight Time (“EDT”). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 (Domestic) 312-470-0178 (International) 800-391-9853 (Domestic Replay) 203-369-3269 (Internati.

Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter Results on July 19, 2023

Boston Scientific

Centene

HCA Healthcare

Humana

Intuitive Surgical

Surgery Partners

Smith & Nephew

Tenet Healthcare

Zimmer Biomet Hlds

After a pandemic pause, hip and knee replacements are back. Long-postponed surgeries are being rescheduled, which is bad for business at insurance companies like UnitedHealth Group Inc. NYSE: UNH, but potentially good business for surgery centers like Surgery Partners Inc. NASDAQ: SGRY and companies like Zimmer Biomet Holdings Inc. NYSE: ZBH that manufacture joint-replacement technologies.

Surgical Centers, Med-Tech Stocks Up On Pent-Up Surgical Demand

CVS Health

Shares of UnitedHealth, Humana, Elevance Health and CVS Health all declined, while medical device manufacturers and hospital operators edged higher.

Health insurance stocks slide after UnitedHealth warns more surgeries will drive up medical costs

Cigna

Goldman Sachs

Insurance stocks are plunging nearly across the board today. This appears to be true whether we're talking about sector leaders like Humana (NYSE: HUM ), UnitedHealth (NYSE: UNH ), Elevance Health (NYSE: ELV ) and Cigna (NYSE: CI ) or other smaller names in the space.

Why Are Insurance Stocks HUM, UNH, ELV, CI Down Today?

UnitedHealth's stock fell 7% Wednesday after saying an uptick in surgeries could squeeze revenues.

Health Insurance Stocks Tumble Over Spike In Surgeries Delayed By Pandemic

Community Health Systems

Seniors are finally catching up on surgery for problems with their knees and hips they delayed during the pandemic — and that means higher costs for health insurers.

Seniors are finally catching up on delayed surgeries. That's bad news for health insurers.

F&G Annuities & Life Inc

Fidelity National Financial

Lithia Motors

Brave Warrior Advisors, the firm led by Glenn Greenberg (Trades, Portfolio), disclosed in a regulatory 13F filing that its top trades during the first quarter included boosts to its holdings of Elevance Health Inc. ( ELV , Financial) and F&G Annuities & Life Inc. ( FG , Financial). The firm also reduced its positions in HCA Healthcare Inc. ( HCA , Financial), Fidelity National Financial Inc. ( FNF , Financial) and Lithia Motors Inc. ( LAD , Financial).

Top 5 Trades of Glenn Greenberg's Firm in the 1st Quarter

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) announced today that senior management is scheduled to present at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, California on June 13th at 10:00 a.m. Pacific Daylight Time (PDT)/1:00 p.m. Eastern Daylight Time (EDT). All interested parties are invited to listen to a live webcast of the presentation by visiting www.elevancehealth.com and selecting the “Investors” link. You may also access the link here. For th.

Elevance Health Announces Appearance at Goldman Sachs 44th Annual Global Healthcare Conference

Although Elevance Health, Inc. remains theoretically undervalued, various of its previous tailwinds are softening. Healthcare insurance prices have reached their cyclical peak, while the yield curve presents significant challenges to Elevance's investment portfolio. Elevance has been active in the M&A market with the divestiture of its life disability business and a "new markets" acquisition. Nevertheless, evidence suggests that success is not guaranteed.

Elevance Health: A Critical Update (Rating Downgrade)

INDIANAPOLIS--(BUSINESS WIRE)-- #MentalHealth--The Elevance Health Foundation, the philanthropic arm of Elevance Health Inc., today announces the expansion of its substance use disorder grants through an additional $5.7 million in awards. Each grant will address substance use disorder, focusing on at least one of the following themes: access to care, quality of treatment, and youth prevention and early intervention. This second phase of grants is a part of the $30 million the Foundation plans to invest through.

Elevance Health Foundation Grows Substance Use Disorder Partnership Programs Through Second Phase of Grants

DexCom

Exact Sciences

Eli Lilly

The Baron Health Care Fund's first five years have been exceptional in every sense of the word. Launched in spring 2018, the fund has navigated around the COVID-19 pandemic, a biotech initial public offering market that boomed and fizzled, and D.C.

News for Elevance Health Inc Stock (ELV)